Ken Tsuchiya
Overview
Explore the profile of Ken Tsuchiya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
2108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakurada T, Zhao J, Tu C, Bieber B, Cheetham M, Pisoni R, et al.
Sci Rep
. 2024 Dec;
14(1):30109.
PMID: 39627492
Effects of the initial peritoneal dialysis (PD) prescription on clinical outcomes are unknown in Japan. We conducted a cohort study using data from Peritoneal Dialysis Outcomes and Practice Patterns Study....
2.
Nitta K, Kataoka H, Manabe S, Makabe S, Akihisa T, Ushio Y, et al.
Clin Exp Nephrol
. 2024 Sep;
29(1):75-82.
PMID: 39322826
Background: Serum phosphate (P) levels are generally lower in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney disorders, potentially masking the clinical significance of hyperphosphatemia. This study aimed...
3.
Nakatani S, Kawano H, Sato M, Hoshino J, Nishio S, Miura K, et al.
Clin Exp Nephrol
. 2024 May;
28(10):1004-1015.
PMID: 38734869
Background: Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are major genetic polycystic kidney diseases that can progress to end-stage kidney disease (ESKD). Longitudinal data...
4.
Ogawa C, Tsuchiya K, Tomosugi N, Maeda K
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338786
In vivo iron levels can be adjusted through intestinal iron absorption to be maintained at a suitable level; however, optimal iron levels in hemodialysis (HD) patients are unclear. In this...
5.
Ushio Y, Kataoka H, Akagawa H, Sato M, Manabe S, Kawachi K, et al.
J Nephrol
. 2024 Feb;
37(4):983-992.
PMID: 38315279
Background: Recently, the importance of attribute-based medicine has been emphasized. The effects of early-onset intracranial aneurysms on patients can be significant and long-lasting. Herein, we compared the factors associated with...
6.
Naganuma T, Takemoto Y, Kamada N, Kabata D, Shintani A, Ota K, et al.
Blood Purif
. 2024 Feb;
53(6):527-532.
PMID: 38310867
Introduction: Recent advances in dialysis therapy have made it possible to remove middle molecules. Removal of small-middle molecules, such as β2-microglobulin, can now be achieved with conventional hemodialysis (HD), and...
7.
Domoto S, Yamaguchi J, Tsuchiya K, Inagaki Y, Nakamae K, Hirota M, et al.
J Cardiol
. 2024 Jan;
84(2):93-98.
PMID: 38215966
Background: Dialysis patients undergoing transcatheter aortic valve replacement (TAVR) face increased risk and have poorer outcomes than non-dialysis patients. Moreover, TAVR in dialysis patients using an alternative approach is considered...
8.
Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, et al.
Nephrol Dial Transplant
. 2023 Nov;
39(6):1008-1015.
PMID: 37935473
Background: Tolvaptan, a vasopressin V2 receptor antagonist, is used for treating autosomal dominant polycystic kidney disease (ADPKD). We focused on changes in urinary osmolality (U-Osm) after tolvaptan initiation to determine...
9.
Kataoka H, Shimada Y, Kimura T, Nishio S, Nakatani S, Mochizuki T, et al.
Clin Exp Nephrol
. 2023 Nov;
28(1):82-83.
PMID: 37924433
No abstract available.
10.
Kataoka H, Shimada Y, Kimura T, Nishio S, Nakatani S, Mochizuki T, et al.
Clin Exp Nephrol
. 2023 Jun;
27(10):809-818.
PMID: 37368094
Background: Clinical practice guidelines recommend antihypertensive and tolvaptan therapies for patients with autosomal dominant polycystic kidney disease (ADPKD) in Japan. However, tolvaptan therapy may pose an economic burden. The Japanese...